Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case report.

This article discusses a case report on the use of bispecific CAR-T cell therapy in a patient with refractory myasthenia gravis (MG), an autoimmune neuromuscular disorder. The patient experienced sustained disappearance of symptoms and anti-acetylcholine receptor antibodies after receiving the therapy. The study suggests that bispecific CAR-T cell therapy has the potential to be an effective treatment for MG and other diseases characterized by autoreactive B cells and autoantibodies. [Extracted from the article]